Burrows, Alyssa G.
Linton, Sophia
Thiele, Jenny
Sheth, Prameet M.
Evans, Gerald A.
Archer, Stephen
Doliszny, Katharine M.
Finlayson, Marcia
Flynn, Leslie
Huang, Yun
Kasmani, Azim
Hugh Guan, T.
Maier, Allison
Hansen-Taugher, Adrienne
Moore, Kieran
Sanfilippo, Anthony
Snelgrove-Clarke, Erna
Tripp, Dean A.
Walker, David M. C.
Vanner, Stephen
Ellis, Anne K. http://orcid.org/0000-0002-0725-2353
Article History
Received: 30 March 2022
Accepted: 13 February 2023
First Online: 29 March 2023
Declarations
:
: The Queen’s University Health Sciences Research Ethics Board approved this study. Verbal consent was obtained from participants prior to their enrollment and participation in this study.
: DAT and AKE have the following disclosures that pose no conflict of interest to the current manuscript. DAT speaker for ALK, ABBVIE, ROHE. AKE has participated in the advisory boards for ALK Abello, AstraZeneca, Aralez, Bausch Health, Circassia Ltd, GlaxoSmithKline, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm, and Pfizer; has been a speaker for ALK, Aralez, AstraZeneca, Boehringer-Ingelheim, CACME, Meda, Mylan, Merck, Novartis, Pediapharm, Pfizer, The ACADEMY, and Takeda; has received research grants from Bayer LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron, and Sanofi, through her institution; and has served as an independent consultant to Allergy Therapeutics, Bayer LLC, Ora Inc and Regeneron in the past. All remaining authours declare that they have no competing conflicts of interest.